| Literature DB >> 32954067 |
Wairimu Magua1, Mohua Basu1, Stephen O Pastan2, Joyce J Kim1, Kayla Smith1, Jennifer Gander3, Sumit Mohan4,5, Cam Escoffery6, Laura C Plantinga2,7, Taylor Melanson1, Michael D Garber7, Rachel E Patzer1,2,7.
Abstract
INTRODUCTION: The Allocation System Changes for Equity in Kidney Transplantation (ASCENT) trial was a cluster-randomized pragmatic, effectiveness-implementation study designed to test whether a multicomponent educational intervention targeting leadership, clinic staff, and patients in dialysis facilities improved knowledge and awareness of the 2014 Kidney Allocation System (KAS) change.Entities:
Keywords: dialysis; effectiveness-implementation trial; health system intervention; kidney allocation system; kidney transplantation; pragmatic trial
Year: 2020 PMID: 32954067 PMCID: PMC7486341 DOI: 10.1016/j.ekir.2020.06.027
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Figure 1Flow diagram illustrating the number of dialysis facilities that (i) met the inclusion/exclusion criteria during enrollment, (ii) were allocated to the study groups, (iii) participated during follow-up, and (iv) were included as part of the analytic sample. ESRD, end-stage renal disease.
Figure 2Dialysis facility locations were overlaid on cartographic boundaries provided by the US Census Bureau (public domain) and implemented using the USAboundaries R package.
Baseline characteristics among US dialysis facilities included in the ASCENT study by study group, October 2016.
| Baseline characteristics | Baseline participation, | Control group, | Intervention group, |
|---|---|---|---|
| Profit status, | |||
| For-profit | 64 (9.8) | 29 (9.0) | 35 (10.5) |
| Nonprofit | 591 (90.2) | 292 (91.0) | 299 (89.5) |
| Census region, | |||
| Northeast | 27 (4.1) | 13 (4.0) | 14 (4.2) |
| South | 424 (64.7) | 223 (69.5) | 231 (69.2) |
| Midwest | 120 (18.3) | 66 (20.6) | 54 (16.2) |
| West | 54 (8.2) | 19 (5.9) | 35 (10.5) |
| Percentage of families considered to be below the national poverty level (based on ZIP code US Census data), | |||
| <5 | 52 (7.9) | 22 (6.9) | 30 (9.0) |
| 5–10 | 137 (20.9) | 73 (22.7) | 64 (19.2) |
| 10–15 | 174 (26.6) | 85 (26.5) | 89 (26.6) |
| 15–20 | 127 (19.4) | 60 (18.7) | 67 (20.1) |
| >20 | 154 (23.5) | 80 (24.9) | 74 (22.2) |
| Missing | 11 (1.7) | 1 (0.3) | 10 (3.0) |
| Patients, | |||
| ≤50 | 187 (28.5) | 92 (28.7) | 95 (28.4) |
| 51–70 | 157 (24.0) | 76 (23.7) | 81 (24.3) |
| 71–95 | 147 (22.4) | 73 (22.7) | 74 (22.2) |
| <95 | 148 (22.6) | 73 (22.7) | 75 (22.5) |
| Missing | 16 (2.4) | 7 (2.2) | 9 (2.7) |
| Staff, | |||
| ≤10 | 170 (26.0) | 87 (27.1) | 83 (24.9) |
| 11–15 | 215 (32.8) | 97 (30.2) | 118 (35.3) |
| 16–20 | 124 (18.9) | 66 (20.6) | 58 (17.4) |
| >20 | 123 (18.8) | 61 (19.0) | 62 (18.6) |
| Missing | 23 (3.5) | 10 (3.1) | 13 (3.9) |
| Percent of patients with comorbidities, quartiles | |||
| Diabetes, | |||
| <50 | 149 (22.7) | 71 (22.1) | 78 (23.4) |
| 50–55.34 | 166 (25.3) | 83 (25.9) | 83 (24.9) |
| 55.34–61.32 | 160 (24.4) | 74 (23.1) | 86 (25.7) |
| >61.32 | 159 (24.3) | 85 (26.5) | 74 (22.2) |
| Missing | 21 (3.2) | 8 (2.5) | 13 (3.9) |
| Hypertension, | |||
| <84.71 | 158 (24.1) | 72 (22.4) | 86 (25.7) |
| 84.71–89.19 | 164 (25.0) | 90 (28.0) | 74 (22.2) |
| 89.19–92.86 | 156 (23.8) | 70 (21.8) | 86 (25.7) |
| >92.86 | 156 (23.8) | 81 (25.2) | 75 (22.5) |
| Missing | 21 (3.2) | 8 (2.5) | 13 (3.9) |
| Congestive heart failure, | |||
| <22.50 | 155 (23.7) | 71 (22.1) | 84 (25.1) |
| 22.50–29.17 | 161 (24.6) | 85 (26.5) | 76 (22.8) |
| 29.17–36.84 | 157 (24.0) | 80 (24.9) | 77 (23.1) |
| >36.84 | 160 (24.4) | 77 (24.0) | 83 (24.9) |
| Missing | 22 (3.4) | 8 (2.5) | 14 (4.2) |
| Chronic obstructive pulmonary disease, | |||
| <5.33 | 148 (22.6) | 71 (22.1) | 77 (23.1) |
| 5.33–9.00 | 149 (22.7) | 78 (24.3) | 71 (21.3) |
| 9.00–13.31 | 150 (22.9) | 75 (23.4) | 75 (22.5) |
| >13.31 | 155 (23.7) | 75 (23.4) | 80 (24.0) |
| Missing | 53 (8.1) | 22 (6.9) | 31 (9.3) |
| Cancer, | |||
| <3.7740 | 152 (23.2) | 67 (20.9) | 85 (25.4) |
| 3.77–6.25 | 135 (20.6) | 74 (23.1 | 61 (18.3) |
| 6.25–9.09 | 153 (23.4) | 74 (23.1) | 79 (23.7) |
| >9.09 | 143 (21.8) | 69 (21.5) | 74 (22.2) |
| Missing | 72 (11.0) | 37 (11.5) | 35 (10.5) |
| Insurance type, mean (SD) | |||
| Medicare | 43.7 (35.0) | 45.4 (37.3) | 42.2 (32.7) |
| Medicaid | 30.9 (26.3) | 30.8 (26.4) | 31.0 (26.2) |
| Employer-based | 22.0 (19.9) | 22.5 (20.7) | 21.5 (19.2) |
| Other insurance | 6.5 (11.0) | 6.3 (8.3) | 6.7 (13.2) |
| Uninsured | 10.4 (11.6) | 10.7 (11.7) | 10.1 (11.5) |
ASCENT, Allocation System Changes for Equity in Kidney Transplantation.
Characteristics of providers who completed the baseline survey from 655 dialysis facilities in all 18 ESRD Networks by study group, October 2016
| Baseline characteristics, | Baseline participation, | Control group, | Intervention group, |
|---|---|---|---|
| Sex | |||
| Male | 147 (21.3) | 74 (21.6) | 73 (21.0) |
| Female | 508 (73.6) | 245 (71.6) | 263 (75.6) |
| Missing | 35 (5.1) | 23 (6.7) | 12 (3.4) |
| Race | |||
| White | 415 (60.1) | 199 (58.2) | 216 (62.1) |
| African American | 87 (12.6) | 46 (13.5) | 41 (11.8) |
| Hispanic | 42 (6.1) | 19 (5.6) | 23 (6.6) |
| Asian | 58 (8.4) | 27 (7.9) | 31 (8.9) |
| Other | 20 (2.9) | 12 (3.5) | 8 (2.3) |
| Missing | 68 (9.9) | 39 (11.4) | 29 (8.3) |
| Professional role | |||
| Medical director | 119 (17.2) | 59 (17.3) | 60 (17.2) |
| Nurse manager | 339 (49.1) | 175 (51.2) | 164 (47.1) |
| Facility administrator | 120 (17.4) | 59 (17.3) | 61 (17.5) |
| Social worker | 91 (13.2) | 40 (11.7) | 51 (14.7) |
| Other staff | 21 (3.0) | 9 (2.6) | 12 (3.4) |
| Length of time in role, yr | |||
| <1 | 108 (15.7) | 51 (14.9) | 57 (16.4) |
| 1–5 | 333 (48.3) | 170 (49.7) | 163 (46.8) |
| 5–10 | 120 (17.4) | 52 (15.2) | 68 (19.5) |
| ≥10 | 129 (18.7) | 69 (20.2) | 60 (17.2) |
ESRD, end-stage renal disease.
Mean difference in staff knowledge gap between the dialysis facility intervention (50.4%) and control group (49.6%) at follow-up minus mean difference of knowledge gap at baseline using multiple imputation pooling 10 datasets over 50 iterations for providers from 655 dialysis in all 18 ESRD Networks in the lowest national tertile (<15.2%), October 2016 to May 2017
| Description | Estimate | 95% CI | |
|---|---|---|---|
| Estimated treatment effect | 0.25 | 0.11–0.48 | 0.039 |
| Intervention vs. control group | −0.16 | −0.36 to 0.03 | 0.104 |
| Follow-up vs. baseline | 0.63 | 0.47–0.80 | <0.001 |
| Covariates: sex, role, length of time in role, race | |||
| Male vs. female | −0.07 | −0.33 to 0.18 | 0.562 |
| Provider role vs. medical director | |||
| Nurse manager | −1.00 | −1.30 to −0.69 | <0.001 |
| Facility administrator | −0.92 | −1.23 to −0.61 | <0.001 |
| Social worker | −0.48 | −0.82 to −0.13 | 0.008 |
| Other | −0.98 | −1.40 to −0.57 | <0.001 |
| Length of time in role vs. shortest length of time in role (<1 yr) | |||
| 1 to <5 | 0.22 | 0.04 | 0.016 |
| 5 to <10 | 0.12 | −0.10 to 0.34 | 0.282 |
| ≥10 | 0.35 | 0.12 | 0.003 |
| Race vs. white | |||
| African American | −0.43 | −0.64 to −0.22 | <0.001 |
| Hispanic | −0.56 | −0.85 to −0.27 | <0.001 |
| Asian | −0.33 | −0.61 to −0.05 | 0.023 |
| Other | −0.04 | −0.40 to 0.32 | 0.819 |
CI, confidence interval; ESRD, end-stage renal disease.
The treatment effect is defined as the mean difference in knowledge between the intervention and the control group at follow-up minus the mean difference in knowledge between the intervention and control group at baseline.
The lower-order terms are a result of the treatment effect, which is modeled as an interaction of time and study group.